Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis

Alla Mitrofanova, Judith Molina, Javier Varona Santos, Johanna Guzman, Ximena A. Morales, G. Michelle Ducasa, Jonathan Bryn, Alexis Sloan, Ion Volosenco, Jin Ju Kim, Mengyuan Ge, Shamroop K. Mallela, Matthias Kretzler, Sean Eddy, Sebastian Martini, Patricia Wahl, Santiago Pastori, Armando J Mendez, George W Burke, Sandra M Merscher-gomezAlessia Fornoni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hereditary Nephritis
Focal Segmental Glomerulosclerosis
Cyclodextrins
Kidney Diseases
Cholesterol
Kidney
Diabetic Nephropathies
Lipid Metabolism
Renal Insufficiency
Kidney Glomerulus
Lipids
Kidney Cortex
Albuminuria
Microarray Analysis
Proteinuria
Knockout Mice
Doxorubicin
Genes
Fibrosis
Pharmacology

Keywords

  • Alport syndrome
  • cholesterol metabolism
  • FSGS
  • hydroxypropyl beta cyclodextrin
  • renal function

ASJC Scopus subject areas

  • Nephrology

Cite this

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. / Mitrofanova, Alla; Molina, Judith; Varona Santos, Javier; Guzman, Johanna; Morales, Ximena A.; Ducasa, G. Michelle; Bryn, Jonathan; Sloan, Alexis; Volosenco, Ion; Kim, Jin Ju; Ge, Mengyuan; Mallela, Shamroop K.; Kretzler, Matthias; Eddy, Sean; Martini, Sebastian; Wahl, Patricia; Pastori, Santiago; Mendez, Armando J; Burke, George W; Merscher-gomez, Sandra M; Fornoni, Alessia.

In: Kidney International, 01.01.2018.

Research output: Contribution to journalArticle

Mitrofanova, A, Molina, J, Varona Santos, J, Guzman, J, Morales, XA, Ducasa, GM, Bryn, J, Sloan, A, Volosenco, I, Kim, JJ, Ge, M, Mallela, SK, Kretzler, M, Eddy, S, Martini, S, Wahl, P, Pastori, S, Mendez, AJ, Burke, GW, Merscher-gomez, SM & Fornoni, A 2018, 'Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis', Kidney International. https://doi.org/10.1016/j.kint.2018.06.031
Mitrofanova, Alla ; Molina, Judith ; Varona Santos, Javier ; Guzman, Johanna ; Morales, Ximena A. ; Ducasa, G. Michelle ; Bryn, Jonathan ; Sloan, Alexis ; Volosenco, Ion ; Kim, Jin Ju ; Ge, Mengyuan ; Mallela, Shamroop K. ; Kretzler, Matthias ; Eddy, Sean ; Martini, Sebastian ; Wahl, Patricia ; Pastori, Santiago ; Mendez, Armando J ; Burke, George W ; Merscher-gomez, Sandra M ; Fornoni, Alessia. / Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. In: Kidney International. 2018.
@article{660df456687145a8ab8775e75ce3d316,
title = "Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis",
abstract = "Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.",
keywords = "Alport syndrome, cholesterol metabolism, FSGS, hydroxypropyl beta cyclodextrin, renal function",
author = "Alla Mitrofanova and Judith Molina and {Varona Santos}, Javier and Johanna Guzman and Morales, {Ximena A.} and Ducasa, {G. Michelle} and Jonathan Bryn and Alexis Sloan and Ion Volosenco and Kim, {Jin Ju} and Mengyuan Ge and Mallela, {Shamroop K.} and Matthias Kretzler and Sean Eddy and Sebastian Martini and Patricia Wahl and Santiago Pastori and Mendez, {Armando J} and Burke, {George W} and Merscher-gomez, {Sandra M} and Alessia Fornoni",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.kint.2018.06.031",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis

AU - Mitrofanova, Alla

AU - Molina, Judith

AU - Varona Santos, Javier

AU - Guzman, Johanna

AU - Morales, Ximena A.

AU - Ducasa, G. Michelle

AU - Bryn, Jonathan

AU - Sloan, Alexis

AU - Volosenco, Ion

AU - Kim, Jin Ju

AU - Ge, Mengyuan

AU - Mallela, Shamroop K.

AU - Kretzler, Matthias

AU - Eddy, Sean

AU - Martini, Sebastian

AU - Wahl, Patricia

AU - Pastori, Santiago

AU - Mendez, Armando J

AU - Burke, George W

AU - Merscher-gomez, Sandra M

AU - Fornoni, Alessia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.

AB - Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.

KW - Alport syndrome

KW - cholesterol metabolism

KW - FSGS

KW - hydroxypropyl beta cyclodextrin

KW - renal function

UR - http://www.scopus.com/inward/record.url?scp=85054423623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054423623&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.06.031

DO - 10.1016/j.kint.2018.06.031

M3 - Article

C2 - 30301568

AN - SCOPUS:85054423623

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -